Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732904 | SCV000860902 | uncertain significance | not provided | 2018-04-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001070216 | SCV001235433 | uncertain significance | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2024-12-23 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 61 of the SYNE1 protein (p.Val61Ile). This variant is present in population databases (rs151156420, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with SYNE1-related conditions. ClinVar contains an entry for this variant (Variation ID: 596927). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000732904 | SCV001826894 | uncertain significance | not provided | 2024-12-18 | criteria provided, single submitter | clinical testing | Reported previously as a heterozygous variant in a patient with peripheral cone dystrophy who also harbored multiple heterozygous variants in other genes (PMID: 30116628); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 30116628) |
Ambry Genetics | RCV002535299 | SCV003625278 | uncertain significance | Inborn genetic diseases | 2021-08-13 | criteria provided, single submitter | clinical testing | The c.181G>A (p.V61I) alteration is located in exon 4 (coding exon 3) of the SYNE1 gene. This alteration results from a G to A substitution at nucleotide position 181, causing the valine (V) at amino acid position 61 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000732904 | SCV003825193 | uncertain significance | not provided | 2020-09-14 | criteria provided, single submitter | clinical testing |